Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 3 (2006), Issue 5 (May)

1. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy.
   J Clin Oncol, 24(13): 2079-83. [Abstract] [Full-text]
2. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
   J Clin Oncol, 24(13): 2044-51. [Abstract] [Full-text]
3. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
   J Clin Oncol, 24(13): 2038-43. [Abstract] [Full-text]
4. Acute respiratory distress syndrome due to pulmonary involvement by neoplastic plasma cells in multiple myeloma.
   Thorax, 61(5): 455-6. [Abstract] [Full-text]
5. Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond.
   Lancet Oncol, 7(5): 416-24. [Abstract] [Full-text]
6. Corticotropin-producing pulmonary gangliocytic paraganglioma associated with Cushing's syndrome.
   Hum Pathol, 37(5): 623-6. [Abstract] [Full-text]
7. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas.
   Hum Pathol, 37(5): 542-6. [Abstract] [Full-text]
8. SEL1L expression in non-small cell lung cancer.
   Hum Pathol, 37(5): 505-12. [Abstract] [Full-text]
9. The evaluation and treatment implications of isolated pulmonary nodules in patients with a recent history of breast cancer.
   Am J Surg, 191(5): 641-5. [Abstract] [Full-text]
10. Validation of a model of lung cancer risk prediction among smokers.
    J Natl Cancer Inst, 98(9): 637-40. [Abstract] [Full-text]
11. Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study.
    Br J Cancer, 94(9): 1263-6. [Abstract] [Full-text]
12. Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.
    Br J Cancer, 94(9): 1267-71. [Abstract] [Full-text]
13. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
    Cancer, 106(10): 2208-17. [Abstract] [Full-text]
14. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
    Cancer, 106(10): 2200-7. [Abstract] [Full-text]
15. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Cancer, 106(10): 2190-9. [Abstract] [Full-text]
16. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases.
    J Thorac Cardiovasc Surg, 131(5): 1014-20. [Abstract] [Full-text]
17. Percutaneous cryoablation of small pulmonary malignant tumors under computed tomographic guidance with local anesthesia for nonsurgical candidates.
    J Thorac Cardiovasc Surg, 131(5): 1007-13. [Abstract] [Full-text]
18. Biologic effects of radiofrequency thermal ablation on non-small cell lung cancer: results of a pilot study.
    J Thorac Cardiovasc Surg, 131(5): 1002-6. [Abstract] [Full-text]
19. Breath-hold single-photon emission tomography and computed tomography for predicting residual pulmonary function in patients with lung cancer.
    J Thorac Cardiovasc Surg, 131(5): 994-1001. [Abstract] [Full-text]
20. Clinicopathologic study of resected, peripheral, small-sized, non-small cell lung cancer tumors of 2 cm or less in diameter: pleural invasion and increase of serum carcinoembryonic antigen level as predictors of nodal involvement.
    J Thorac Cardiovasc Surg, 131(5): 988-93. [Abstract] [Full-text]
21. Postoperative pneumonia after major lung resection.
    Am J Respir Crit Care Med, 173(10): 1161-9. [Abstract] [Full-text]
22. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer.
    Chest, 129(5): 1305-12. [Abstract] [Full-text]
23. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications.
    Chest, 129(5): 1274-81. [Abstract] [Full-text]
24. Patient perspectives on management of pneumothorax in lymphangioleiomyomatosis.
    Chest, 129(5): 1267-73. [Abstract] [Full-text]
25. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.
    Am J Clin Pathol, 125(6): 860-5. [Abstract] [Full-text]
26. Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth.
    Am J Clin Pathol, 125(6): 847-54. [Abstract] [Full-text]
27. The potential for dose escalation in lung cancer as a result of systematically reducing margins used to generate planning target volume.
    Int J Radiat Oncol Biol Phys, 65(2): 573-86. [Abstract] [Full-text]
28. Beam angle optimization and reduction for intensity-modulated radiation therapy of non-small-cell lung cancers.
    Int J Radiat Oncol Biol Phys, 65(2): 561-72. [Abstract] [Full-text]
29. Phase I study of hypofractionated dose-escalated thoracic radiotherapy for limited-stage small-cell lung cancer.
    Int J Radiat Oncol Biol Phys, 65(2): 466-73. [Abstract] [Full-text]
30. p53 mutation spectra for squamous cell carcinomas at different levels of human bronchial branches.
    Int J Cancer, 119(3): 501-7. [Abstract] [Full-text]
31. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.
    Int J Cancer, 119(3): 718-21. [Abstract] [Full-text]
32. Lung cancer death rates in lifelong nonsmokers.
    J Natl Cancer Inst, 98(10): 691-9. [Abstract] [Full-text]
33. Transforming growth factor-beta1 induces the non-classical secretion of peroxiredoxin-I in A549 cells.
    Biochem Biophys Res Commun, 345(1): 118-23. [Abstract] [Full-text]
34. Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel.
    Am J Clin Pathol, 125(5): 682-92. [Abstract] [Full-text]
35. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity.
    J Clin Oncol, 24(15): 2245-51. [Abstract] [Full-text]
36. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
    J Clin Oncol, 24(15): 2237-44. [Abstract] [Full-text]
37. Proximal nerve root capillary hemangioma presenting as a lung mass with bandlike chest pain: case report and review of literature.
    Surg Neurol, 65(6): 584-9; discussion 589. [Abstract] [Full-text]
38. Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol, 58(3): 285-91. [Abstract] [Full-text]
39. Effect of interleukin-18 on metastasis of mouse osteosarcoma cells.
    Cancer Immunol Immunother, 55(9): 1151-8. [Abstract] [Full-text]
40. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
    Cancer Chemother Pharmacol, 58(3): 368-73. [Abstract] [Full-text]
41. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
    Cancer Chemother Pharmacol, 58(3): 361-7. [Abstract] [Full-text]
42. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.
    Cancer Immunol Immunother, 55(9): 1122-31. [Abstract] [Full-text]
43. Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome.
    Am J Kidney Dis, 47(6): 1072-4. [Abstract] [Full-text]
44. Sirolimus for Kaposi's sarcoma.
    J Heart Lung Transplant, 25(6): 726-9. [Abstract] [Full-text]
45. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
    Cancer, 106(11): 2421-7. [Abstract] [Full-text]
46. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer.
    Cancer, 106(11): 2428-36. [Abstract] [Full-text]
47. Uncommon V599E BRAF mutations in Japanese patients with lung cancer.
    J Surg Res, 133(2): 203-6. [Abstract] [Full-text]
48. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Hum Pathol, 37(6): 755-63. [Abstract] [Full-text]
49. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
    J Clin Oncol, 24(16): 2549-56. [Abstract] [Full-text]
50. Recent trends in the treatment of advanced lung cancer.
    Cancer Sci, 97(6): 448-52. [Abstract] [Full-text]
51. Degradation of insulin-like growth factor-I receptor occurs via ubiquitin-proteasome pathway in human lung cancer cells.
    J Cell Physiol, 208(2): 354-62. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.